Peptide based vaccine that incorporates one or several highly conserved CD8+ T cells
epitopes to induce potent cytotoxic T lymphocyte (CTL) response is desirable for some …

Vaccines that elicit robust CD8+ T cell responses are desirable for protection against
infectious diseases and cancers. However, most vaccine adjuvants fail to elicit robust CD8+ …

Improving CD8+ T cell responses activated by subunit vaccination is crucial for improving
vaccine efficacy and safety. Here we report a carrier-adjuvant system composed of self …

Dendritic cells (DCs) can process the antigens of cancer vaccine and thus stimulate the
CD8+ T cells to recognize and kill the tumor cells that express these antigens. However, lack …

Peptide vaccines are broadly used as alternatives to traditional vaccines for cancer
immunotherapy; however, the clinical translation of peptide vaccination is still limited by the …

Educating our immune system via vaccination is an attractive approach to combat infectious
diseases. Eliciting antigen specific cytotoxic T cells (CTLs), CD8+ effector T cells, is essential …

Efficient delivery of subunit vaccines to dendritic cells (DCs) is necessary to improve vaccine
efficacy, because the vaccine antigen alone cannot induce sufficient protective immunity …

It is now clear that CD8+ T cells are crucial for therapeutic immunity against chronic viral
infections and/or tumors. We reason that a strategy capable of improving CD8+ T cell …

Background To induce potent epitope-specific T cell immunity by a peptide-based vaccine,
epitope peptides must be delivered efficiently to antigen-presenting cells (APCs) in vivo …

Dendritic cells (DCs) are professional antigen-presenting cells with antigen recognition
molecules on the surface. Clec9a is selectively expressed on mouse CD8a+ DCs and …